Life Extension Magazine November 2006
By Julius G. Goepp, MD
Selenium Shows Promise in Preventing Cancer
Selenium’s antioxidant properties have spurred great interest in its potential to prevent cancer. This is not surprising, given our increasing awareness that cancer is caused and promoted by the same cascade of events—oxidative stress and cytokine release—that produces the autoimmune and other inflammatory conditions just discussed.
To date, more than 100 animal studies have investigated selenium’s effects on the mechanisms responsible for initiating cancer. In the overwhelming majority of these studies, selenium reduced tumor incidence and tissue changes that lead to cancer.8,37 The high incidence of various cancers in selenium-deficient regions of the world strongly supports a cancer-preventive role for selenium in humans as well, and epidemiological studies have demonstrated reductions in the rates of, and mortality from, all cancers in populations receiving selenium supplementation.38
Selenium Prevents and Slows Prostate Cancer
Additional studies of selenium’s effects in helping to prevent specific cancers have yielded results that are even more positive.
One of the most dramatic of these was the unexpected outcome of a study designed to examine selenium’s impact on skin cancer.39 This study of 1,312 individuals who received 200 mcg of selenium daily or a placebo showed no effect against skin cancer, but demonstrated “striking” results in preventing prostate cancer, the most common cancer in American men.40,41 The overall risk of prostate cancer was almost 50% lower in the supplemented group than in the controls, though the result was significant only in men who had relatively low prostate-specific antigen (PSA) levels and low initial selenium levels.
This result prompted a re-analysis of data from the SU.VI.MAX study, with a specific look at prostate cancer.42 Within that group, 5,141 men took the selenium-containing supplement or placebo for eight years, and biochemical markers of prostate disease were measured at the beginning and end of the study. Overall, a slight reduction in prostate cancer risk was reported; however, among men who had normal PSA levels at the study’s outset, a significant risk reduction of nearly 50% was recorded.
A 2005 study focusing on selenium’s effects in preventing prostate cancer dramatically confirmed this protective effect.43 Forty-eight patients with early prostate cancer took selenium, vitamin E, both L-selenomethionine and vitamin E, or a placebo for three to six weeks before undergoing prostatectomy (removal of the prostate). Levels of cancer markers were measured and compared with 29 healthy control subjects. The startling result was a change in classification from cancerous to healthy in the serum markers of disease in the men who took supplements compared to those who did not.
In addition to its clear role in preventing prostate cancer, selenium may slow the progression of already established prostate cancer. In a six-week trial, 37 men with prostate cancer and increasing PSA levels were given either a placebo or an antioxidant supplement containing selenium, plant estrogens, and other antioxidants.44 In the supplemented group, male hormone levels (known to stimulate prostate cancer growth) were lower during treatment. In addition, free PSA levels rose during treatment with the placebo, but decreased during antioxidant supplementation.
These studies, along with recent findings that selenium is selectively concentrated in prostate tissue,45 strongly support a role for selenium supplementation in both preventing and slowing the progression of prostate cancer.
Selenium Protects Against Lung Cancer
Lung cancer is the most common cause of cancer death in the world.46 The previously mentioned skin cancer study also demonstrated that selenium supplementation reduced rates of lung and colorectal cancers.39 Lung cancer is associated with antioxidative stress and low levels of antioxidants, including selenium.47 A 1993 study demonstrated a 50% reduction in lung cancer occurrence in people with the highest dietary selenium intake compared to those with the lowest intake.48 This finding is supported by a more recent study of more than 27,000 male smokers who were followed for nearly 15 years. In this study, researchers found that lung cancer risk was significantly lower in patients who had the highest intake of antioxidant vitamins and selenium.49
Selenium supplementation was highly effective in preventing lung cancer in a region of China where very low natural selenium concentrations contribute to some of the world’s highest rates of lung cancer. Forty Chinese tin miners were randomly assigned to receive either 300 mcg of selenium or a placebo daily for one year. As expected, selenium blood levels rose dramatically in the supplemented miners, while serum levels of the antioxidant enzyme glutathione peroxidase increased by 156%. At the same time, levels of lipid peroxide (a measure of cell membrane damage that leads to cancer) were reduced by 75% in the supplemented group, and there was laboratory evidence of protection from DNA damage, another prerequisite for cancer formation.50
Moreover, results from the US Nutritional Prevention of Cancer Trial demonstrated a statistically significant reduction in lung cancer incidence with selenium supplementation, with 200 mcg per day cutting the incidence of cancer by nearly 50%.51 A later re-analysis with additional data showed the effect to be most significant in people with low baseline selenium levels, again suggesting that supplementation is preventive when initiated early.37
Selenium Guards Against Colon Cancer
Selenium supplementation has also shown effectiveness in preventing colorectal cancer, the third most common cause of cancer death in the US.52 Glutathione peroxidase, a selenium-containing antioxidant enzyme, is genetically defective in a significant percentage of patients with colon cancer.53 Selenium actually activates the DNA repair mechanisms that help cells protect themselves against colon and other cancers,54 while inducing programmed cell death (apoptosis) in cancerous tissue.55 In an animal model of cancer, selenium-containing broccoli in the diet of laboratory rats protected the animals against chemically induced mammary and colon cancers.56
After demonstrating that patients with colon cancer routinely have selenium deficiencies, and that levels of vital antioxidant enzymes could be increased with selenium supplementation, one research team concluded, “If prospective trials confirm that selenium supplementation reduces colon cancer incidence rates, it may be concluded that selenium supplementation should be recommended for patients at risk.”57
Such confirmation is now beyond doubt. In a 1996 study of 44 patients with colon cancer, half were randomly assigned to receive selenium supplements and half were given a placebo. All the subjects had their tumors surgically removed, and all had abnormally low selenium levels at baseline. The selenium-supplemented patients demonstrated significant increases in anti-cancer immune system cells compared to levels in control patients, suggesting that selenium supplementation boosts cell-mediated immunity.58
More dramatic, unexpected evidence of selenium’s cancer-preventive properties comes from a 2006 study. Seeking to determine the maximum tolerable dose of the anti-cancer drug irinotecan, researchers administered a massive dose of selenomethionine (containing 2200 mcg of selenium) to protect against the drug’s toxicity.59 Selenium supplementation was begun one week before the first dose of irinotecan was administered to colon cancer patients who had previously not responded to chemotherapy. This small study of highly drug-resistant patients produced unexpected responses (one patient out of six showed a partial response to treatment) and disease stabilization. No adverse effects of the high dose were reported. The scientists recommended further study of high-dose selenomethionine to determine the most protective serum concentrations of selenium.
A review of recent research findings suggests that scientists have only begun to tap selenium’s potential as a vital antioxidant mineral.
As scientists continue to discover the many ways in which oxidative stress is related to inflammation and its destructive consequences—from atherosclerosis to prostate, lung, colon, and other cancers—the disease-preventive powers of selenium are likely to receive even greater scrutiny. For now, all health-conscious adults would be well advised to incorporate this vital mineral nutrient in their daily supplement regimen as part of a comprehensive disease-prevention program.
1. Chu FF, Esworthy RS, Doroshow JH. Role of Se-dependent glutathione peroxidases in gastrointestinal inflammation and cancer. Free Radic Biol Med. 2004 Jun 15;36(12):1481-95.
2. El-Bayoumy K, Sinha R, Pinto JT, Rivlin RS. Cancer chemoprevention by garlic and garlic-containing sulfur and selenium compounds. J Nutr. 2006 Mar;136(3 Suppl):864S-9S.
3. Gromer S, Eubel JK, Lee BL, Jacob J. Human selenoproteins at a glance. Cell Mol Life Sci. 2005 Nov;62(21):2414-37.
4. Dodig S, Cepelak I. The facts and controversies about selenium. Acta Pharm. 2004 Dec;54(4):261-76.
5. Finley JW. Bioavailability of selenium from foods. Nutr Rev. 2006 Mar;64(3):146-51.
6. Xia Y, Hill KE, Byrne DW, Xu J, Burk RF. Effectiveness of selenium supplements in a low-selenium area of China. Am J Clin Nutr. 2005 Apr;81(4):829-34.
7. Knekt P, Marniemi J, Teppo L, Heliovaara M, Aromaa A. Is low selenium status a risk factor for lung cancer? Am J Epidemiol. 1998 Nov 15;148(10):975-82.
8. Patterson BH, Levander OA. Naturally occurring selenium compounds in cancer chemoprevention trials: a workshop summary. Cancer Epidemiol Biomarkers Prev. 1997 Jan;6(1):63-9.
9. Russo MW, Murray SC, Wurzelmann JI, Woosley JT, Sandler RS. Plasma selenium levels and the risk of colorectal adenomas. Nutr Cancer. 1997;28(2):125-9.
10. Burguera JL, Burguera M, Gallignani M, Alarcon OM, Burguera JA. Blood serum selenium in the province of Merida, Venezuela, related to sex, cancer incidence and soil selenium content. J Trace Elem Electrolytes Health Dis. 1990 Jun;4(2):73-7.
11. Fleet JC. Dietary selenium repletion may reduce cancer incidence in people at high risk who live in areas with low soil selenium. Nutr Rev. 1997 Jul;55(7):277-9.
12. Jackson MJ, Dillon SA, Broome CS, et al. Are there functional consequences of a reduction in selenium intake in UK subjects? Proc Nutr Soc. 2004 Nov;63(4):513-7.
13. Young KJ, Lee PN. Intervention studies on cancer. Eur J Cancer Prev. 1999 Apr;8(2):91-103.
14. Andriamanalijaona R, Kypriotou M, Bauge C, et al. Comparative effects of 2 antioxidants, selenomethionine and epigallocatechin-gallate, on catabolic and anabolic gene expression of articular chondrocytes. J Rheumatol. 2005 Oct;32(10):1958-67.
15. Black PH. The inflammatory consequences of psychologic stress: Relationship to insulin resistance, obesity, atherosclerosis and diabetes mellitus, type II. Med Hypotheses. 2006;67(4):879-91.
16. Lu J, Jiang C. Selenium and cancer chemoprevention: hypotheses integrating the actions of selenoproteins and selenium metabolites in epithelial and non-epithelial target cells. Antioxid Redox Signal. 2005 Nov;7(11-12):1715-27.
17. Abdulah R, Miyazaki K, Nakazawa M, Koyama H. Chemical forms of selenium for cancer prevention. J Trace Elem Med Biol. 2005;19(2-3):141-50.
18. Turan B, Saini HK, Zhang M, et al. Selenium improves cardiac function by attenuating the activation of NF-kappaB due to ischemia-reperfusion injury. Antioxid Redox Signal. 2005 Sep;7(9-10):1388-97.
19. Gartner R, Angstwurm M. Significance of selenium in intensive care medicine. Clinical studies of patients with SIRS/sepsis syndrome. Med Klin (Munich). 1999 Oct 15;94 Suppl 3:54-7.
20. Maehira F, Miyagi I, Eguchi Y. Selenium regulates transcription factor NF-kappaB activation during the acute phase reaction. Clin Chim Acta. 2003 Aug;334(1-2):163-71.
21. Faure P, Ramon O, Favier A, Halimi S. Selenium supplementation decreases nuclear factor-kappa B activity in peripheral blood mononuclear cells from type 2 diabetic patients. Eur J Clin Invest. 2004 Jul;34(7):475-81.
22. Ryan-Harshman M, Aldoori W. The relevance of selenium to immunity, cancer, and infectious/inflammatory diseases. Can J Diet Pract Res. 2005;66(2):98-102.
23. Heinle K, Adam A, Gradl M, Wiseman M, Adam O. Selenium concentration in erythrocytes of patients with rheumatoid arthritis. Clinical and laboratory chemistry infection markers during administration of selenium. Med Klin (Munich). 1997 Sep 15;92 Suppl 3:29-31.
24. Bacic-Vrca V, Skreb F, Cepelak I, et al. The effect of antioxidant supplementation on superoxide dismutase activity, Cu and Zn levels, and total antioxidant status in erythrocytes of patients with Graves’ disease. Clin Chem Lab Med. 2005;43(4):383-8.
25. Turker O, Kumanlioglu K, Karapolat I, Dogan I. Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses. J Endocrinol. 2006 Jul;190(1):151-6.
26. Duntas LH, Mantzou E, Koutras DA. Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis. Eur J Endocrinol. 2003 Apr;148(4):389-93.
27. Gartner R, Gasnier BC. Selenium in the treatment of autoimmune thyroiditis. Biofactors. 2003;19(3-4):165-70.
28. Vrca VB, Skreb F, Cepelak I, Romic Z, Mayer L. Supplementation with antioxidants in the treatment of Graves’ disease; the effect on glutathione peroxidase activity and concentration of selenium. Clin Chim Acta. 2004 Mar;341(1-2):55-63.
29. Czuczejko J, Halota W, Zachara BA, Staubach-Topczewska E. Plasma selenium concentration, glutathione peroxidase and glutathione S-transferase activities in patients with chronic liver diseases. Pol Merkuriusz Lek. 2002 Oct;13(76):312-5.
30. Czuczejko J, Zachara BA, Staubach-Topczewska E, Halota W, Kedziora J. Selenium, glutathione and glutathione peroxidases in blood of patients with chronic liver diseases. Acta Biochim Pol. 2003;50(4):1147-54.
31. Pemberton PW, Aboutwerat A, Smith A, et al. Oxidant stress in type I autoimmune hepatitis: the link between necroinflammation and fibrogenesis? Biochim Biophys Acta. 2004 Aug 4;1689(3):182-9.
32. Beckett GJ, Arthur JR. Selenium and endocrine systems. J Endocrinol. 2005 Mar;184(3):455-65.
33. Wenzel G, Kuklinski B, Ruhlmann C, Ehrhardt D. Alcohol-induced toxic hepatitis—a “free radical” associated disease. Lowering fatality by adjuvant antioxidant therapy. Z Gesamte Inn Med. 1993 Oct;48(10):490-6.
34. Yu SY, Li WG, Zhu YJ, Yu WP, Hou C. Chemoprevention trial of human hepatitis with selenium supplementation in China. Biol Trace Elem Res. 1989 Apr;20(1-2):15-22.
35. Angstwurm MW, Schottdorf J, Schopohl J, Gaertner R. Selenium replacement in patients with severe systemic inflammatory response syndrome improves clinical outcome. Crit Care Med. 1999 Sep;27(9):1807-13.
36. Borner J, Zimmermann T, Albrecht S, Roesner D. Selenium administration in children with SIRS. Med Klin (Munich). 1999 Oct 15;94 Suppl 3:93-6.
37. Reid ME, Duffield-Lillico AJ, Garland L, et al. Selenium supplementation and lung cancer incidence: an update of the nutritional prevention of cancer trial. Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1285-91.
38. Rayman MP. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc. 2005 Nov;64(4):527-42.
39. Combs GF, Jr., Clark LC, Turnbull BW. Reduction of cancer risk with an oral supplement of selenium. Biomed Environ Sci. 1997 Sep;10(2-3):227-34.
40. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 2003 May;91(7):608-12.
41. Vogt TM, Ziegler RG, Graubard BI, et al. Serum selenium and risk of prostate cancer in U.S. blacks and whites. Int J Cancer. 2003 Feb 20;103(5):664-70.
42. Meyer F, Galan P, Douville P, et al. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer. 2005 Aug 20;116(2):182-6.
43. Kim J, Sun P, Lam YW, et al. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1697-02.
44. Kranse R, Dagnelie PC, van Kemenade MC, et al. Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study. Int J Cancer. 2005 Feb 20;113(5):835-40.
45. Sabichi AL, Lee JJ, Taylor RJ, et al. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2178-84.
46. Winterhalder RC, Hirsch FR, Kotantoulas GK, Franklin WA, Bunn PA, Jr. Chemoprevention of lung cancer--from biology to clinical reality. Ann Oncol. 2004 Feb;15(2):185-96.
47. Della RF, Granata A, Familiari D, et al. Histamine and selenium in lung cancer. Anticancer Res. 2006 Jul;26(4B):2937-42.
48. van den Brandt PA, Goldbohm RA, van’t Veer P, et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Res. 1993 Oct 15;53(20):4860-5.
49. Wright ME, Mayne ST, Stolzenberg-Solomon RZ, et al. Development of a comprehensive dietary antioxidant index and application to lung cancer risk in a cohort of male smokers. Am J Epidemiol. 2004 Jul 1;160(1):68-76.
50. Yu SY, Mao BL, Xiao P, et al. Intervention trial with selenium for the prevention of lung cancer among tin miners in Yunnan, China. A pilot study. Biol Trace Elem Res. 1990 Feb;24(2):105-8.
51. Clark LC, Combs GF, Jr., Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996 Dec 25;276(24):1957-63.
52. Nelson MA, Goulet AC, Jacobs ET, Lance P. Studies into the anticancer effects of selenomethionine against human colon cancer. Ann NY Acad Sci. 2005 Nov;1059:26-32.
53. Hu Y, Benya RV, Carroll RE, Diamond AM. Allelic loss of the gene for the GPX1 selenium-containing protein is a common event in cancer. J Nutr. 2005 Dec;135(12 Suppl):3021S-4S.
54. Fischer JL, Lancia JK, Mathur A, Smith ML. Selenium protection from DNA damage involves a Ref1/p53/Brca1 protein complex. Anticancer Res. 2006 Mar;26(2A):899-904.
55. Goel A, Fuerst F, Hotchkiss E, Boland CR. Selenomethionine induces p53 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cancer Biol Ther. 2006 May;5(5):529-35.
56. Finley JW. Reduction of cancer risk by consumption of selenium-enriched plants: enrichment of broccoli with selenium increases the anticarcinogenic properties of broccoli. J Med Food. 2003;6(1):19-26.
57. Al-Taie OH, Seufert J, Karvar S, et al. Selenium supplementation enhances low selenium levels and stimulates glutathione peroxidase activity in peripheral blood and distal colon mucosa in past and present carriers of colon adenomas. Nutr Cancer. 2003;46(2):125-30.
58. Yu B, Wang M, Li D. The relationship between selenium and immunity in large bowel cancer. Zhonghua Wai Ke Za Zhi. 1996 Jan;34(1):50-3.
59. Fakih MG, Pendyala L, Smith PF, et al. A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors. Clin Cancer Res. 2006 Feb 15;12(4):1237-44.
60. Yilmaz MI, Saglam M, Caglar K, et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis. 2006 Jan;47(1):42-50.
61. Bor MV, Cevik C, Uslu I, Guneral F, Duzgun E. Selenium levels and glutathione peroxidase activities in patients with acute myocardial infarction. Acta Cardiol. 1999 Oct;54(5):271-6.
62. Constans J, Seigneur M, Blann AD, et al. Effect of the antioxidants selenium and beta-carotene on HIV-related endothelium dysfunction. Thromb Haemost. 1998 Dec;80(6):1015-7.
63. de Lorgiril M, Salen P, Accominotti M, et al. Dietary and blood antioxidants in patients with chronic heart failure. Insights into the potential importance of selenium in heart failure. Eur J Heart Fail. 2001 Dec;3(6):661-9.
64. de Lorgiril M, Salen P. Selenium and antioxidant defenses as major mediators in the development of chronic heart failure. Heart Fail Rev. 2006 Mar;11(1):13-7.
65. Locatelli F, Canaud B, Eckardt KU, et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 2003 Jul;18(7):1272-80.
66. Bonomini M, Forster S, De Risio F, et al. Effects of selenium supplementation on immune parameters in chronic uraemic patients on haemodialysis. Nephrol Dial Transplant. 1995;10(9):1654-61.
67. Zachara BA, Salak A, Koterska D, Manitius J, Wasowicz W. Selenium and glutathione peroxidases in blood of patients with different stages of chronic renal failure. J Trace Elem Med Biol. 2004;17(4):291-9.
68. Adamowicz A, Trafikowska U, Trafikowska A, Zachara B, Manitius J. Effect of erythropoietin therapy and selenium supplementation on selected antioxidant parameters in blood of uremic patients on long-term hemodialysis. Med Sci Monit. 2002 Mar;8(3):CR202-5.
69. Zimmermann T, Leonhardt H, Kersting S, Albrecht S, Range U, Eckelt U. Reduction of postoperative lymphedema after oral tumor surgery with sodium selenite. Biol Trace Elem Res. 2005 Sep;106(3):193-203.
70. Bruns F, Buntzel J, Mucke R, Schoenkaes K, Kisters K, Micke O. Selenium in the treatment of head and neck lymphedema. Med Princ Pract. 2004 Jul;13(4):185-90.
71. Micke O, Bruns F, Mucke R, et al. Selenium in the treatment of radiation-associated secondary lymphedema. Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):40-9.
72. Broome CS, McArdle F, Kyle JA, et al. An increase in selenium intake improves immune function and poliovirus handling in adults with marginal selenium status. Am J Clin Nutr. 2004 Jul;80(1):154-62.
73. Bjornstedt M, Odlander B, Kuprin S, Claesson HE, Holmgren A. Selenite incubated with NADPH and mammalian thioredoxin reductase yields selenide, which inhibits lipoxygenase and changes the electron spin resonance spectrum of the active site iron. Biochemistry. 1996 Jul 2;35(26):8511-6.
74. Fleming J, Ghose A, Harrison PR. Molecular mechanisms of cancer prevention by selenium compounds. Nutr Cancer. 2001;40(1):42-9.
75. Harrison PR, Lanfear J, Wu L, Fleming J, McGarry L, Blower L. Chemopreventive and growth inhibitory effects of selenium. Biomed Environ Sci. 1997 Sep;10(2-3):235-45.
76. Spyrou G, Bjornstedt M, Kumar S, Holmgren A. AP-1 DNA-binding activity is inhibited by selenite and selenodiglutathione. FEBS Lett. 1995 Jul 10;368(1):59-63.
77. Cho DY, Jung U, Chung AS. Induction of apoptosis by selenite and selenodiglutathione in HL-60 cells: correlation with cytotoxicity. Biochem Mol Biol Int. 1999 May;47(5):781-93.
78. Ghose A, Fleming J, El-Bayoumy K, Harrison PR. Enhanced sensitivity of human oral carcinomas to induction of apoptosis by selenium compounds: involvement of mitogen-activated protein kinase and Fas pathways. Cancer Res. 2001 Oct 15;61(20):7479-87.
79. Turker O, Kumanlioglu K, Karapolate I, Dogan I. Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses. J Endocrinol. 2006 Jul;190(1):151-6.
80. Sabichi AL, Lee JJ, Taylor RJ, et al. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2178-84.
81. Clausen J, Nielsen SA, Kristensen M. Biochemical and clinical effects of an antioxidative supplementation of geriatric patients. A double blind study. Biol Trace Elem Res. 1989 Apr;20(1-2):135-51.
82. Abdulah R, Miyazaki K, Nakazawa M, Koyama H. Chemical forms of selenium for cancer prevention. J Trace Elem Med Biol. 2005;19(2-3):141-50.
83. Fakih M, Cao S, Durrani FA, Rustum YM. Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors. Clin Colorectal Cancer. 2005 Jul;5(2):132-5.
84. Yin MB, Li ZR, Toth K, et al. Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis. Oncogene. 2006 Apr;25(17):2509-19.